FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial. PMID 40139716 · Rheumatology (Oxford) · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of adjuvant chemotherapy with toad venom injection in the treatment of intermediate and advanced colon cancer and its effect on cellular immunity, PTEN, and PI3k. PMID 39964699 · Anticancer Drugs · 2025-Jul-01 The record is a randomized oncology trial with a drug intervention and reports original results, but it lacks the required primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) as a formal, quantitative outcome. The study reports a 1-year survival rate as a simple proportion without Kaplan-Meier analysis or hazard ratio, which does not meet the time-to-event criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term survival from a randomized controlled trial of lobectomy by video-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer. PMID 39873729 · Eur J Cardiothorac Surg · 2025-Jul-01 The study is a randomized, oncology trial with time-to-event endpoints and is an original result report. However, it compares two surgical techniques (VATS vs. thoracotomy) and does not involve a drug-containing intervention, which is a required criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Three-year Survival Outcomes of Patients With Enhanced Recovery After Surgery Versus Conventional Care in Laparoscopic Distal Gastrectomy: The GISSG1901 Randomized Clinical Trial. PMID 39660451 · Ann Surg · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Identification and Categorization of Technical Errors and Hazard Zones of Robotic Versus Laparoscopic Total Gastrectomy for Gastric Cancer: A Single-center Prospective Randomized Controlled Study. PMID 39513271 · Ann Surg · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Paravertebral Versus EPidural Analgesia in Minimally Invasive Esophageal ResectioN (PEPMEN): A Randomized Controlled Multicenter Trial. PMID 39360422 · Ann Surg · 2025-Jul-01 The study is a randomized trial in esophageal cancer (oncology, human), but the intervention is purely procedural (analgesia techniques), not a drug-containing intervention. The primary outcome is quality of recovery (QoR-40), a patient-reported outcome measure, not a time-to-event efficacy endpoint. Secondary outcomes include quality of life and complications, but no time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, TTP, or time-to-event analyses (Kaplan-Meier, HR) are reported. Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Emerging Role of Multiparametric MRI in the Staging of Bladder Cancer: Insights From the BladderPath Trial. PMID 40861675 · Cureus · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of the "Internet +" nursing model based on user profiling on postoperative recovery in breast cancer: A prospective randomized controlled clinical trial. PMID 40786863 · Int J Nurs Sci · 2025-Jul The study is a randomized, prospective, human oncology trial with primary results. However, it is excluded because it does not meet the core eligibility criteria: it is not reported as a Phase III/IIIb or Phase II/III trial, the intervention is a non-drug 'Internet+' nursing model, and the primary endpoints are quality-of-life and symptom scores (FOP-Q-SF, FCRI-SF, C-PTGI, FACT-B), not a time-to-event efficacy endpoint like OS, PFS, or DFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab in early curative breast cancer: A target trial emulation benchmarked against two randomized clinical trials. PMID 40690519 · PLoS Med · 2025-Jul The record describes an observational analysis (target trial emulation) benchmarked against two existing randomized trials (B-31 and N9831). It is not an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a time-to-event efficacy endpoint. While it discusses and cites Phase III trials, the report itself does not present the results of such a trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial. PMID 40657894 · Clin Transl Sci · 2025-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
B
|
旧查询独有 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Feasibility Randomised Controlled Trial of a New Digital Intervention ('FRAME') to Promote Resilience in Women Treated for Primary Breast Cancer. PMID 40634264 · Psychooncology · 2025-Jul The study is a randomized, human, oncology (breast cancer) feasibility trial, but it is not eligible for the cohort because it is not a Phase III/IIIb or definitive Phase II/III trial, it does not involve a drug-containing intervention (it's a digital/CBT intervention), and it does not report a primary or key secondary time-to-event efficacy endpoint (outcomes are acceptability, feasibility, interpretation bias, resilience, mood, and quality of life). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML. PMID 40629154 · Ann Hematol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Urodynamics tests for the diagnosis and management of male bladder outlet obstruction: long-term follow-up of the UPSTREAM non-inferiority RCT. PMID 40619891 · Health Technol Assess · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma. PMID 40579886 · Hematol Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intermediate-Dose Cytarabine as Postinduction AML Therapy. PMID 40552969 · NEJM Evid · 2025-Jul The record meets all eligibility criteria: it is an original, final report of a randomized, drug-intervention trial in human oncology patients (AML) with a Phase III-level design and a primary time-to-event efficacy endpoint (OS). |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. PMID 40552964 · NEJM Evid · 2025-Jul The record is a prospective observational cohort study (KBP-2020) comparing survival trends over time, not a randomized controlled trial of a specific drug intervention. Although publication types include 'Randomized Controlled Trial', the abstract and methods describe a non-interventional study, and the 'Randomized Controlled Trial' tag is likely a metadata error. It lacks explicit Phase III/IIIb or Phase II/III trial evidence, randomized assignment, or a drug-controlled experimental design. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. PMID 40541214 · Lancet Oncol · 2025-Jul The study is a phase 3 randomized oncology trial with a drug intervention and an original result. However, the primary efficacy endpoint is a categorical response rate (complete response), not a time-to-event endpoint as required by the cohort criteria. Therefore, it is not eligible. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. PMID 40532361 · ESMO Open · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Opioid-free anaesthesia protocol based on thoracic paravertebral block enhances postoperative recovery after breast cancer surgery: A two-center, prospective, randomized, controlled trial. PMID 40532358 · J Clin Anesth · 2025-Jul The study is a randomized, prospective, multicenter trial in breast cancer surgery patients, but it compares anesthetic techniques (opioid-free vs. opioid-based) and does not involve a drug intervention for cancer treatment. The primary endpoint is a quality-of-recovery score (QoR-15), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. PMID 40517778 · Lancet Oncol · 2025-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Tight competition for the first-line treatment of Hodgkin's lymphoma: a comprehensive review of practice-changing developments in recent years. PMID 40506833 · Expert Opin Biol Ther · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma. PMID 40501447 · Future Oncol · 2025-Jul The record describes a randomized controlled trial in oncology with a drug intervention and primary time-to-event efficacy endpoints (PFS, OS). However, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III in the provided title, abstract, publication types, or MeSH terms. The deterministic review signals 'phase3': false and 'phase3_publication_type': false. Without explicit phase evidence from the original report's metadata, the eligibility criterion 'phase3_or_definitive' cannot be established, leading to ineligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Action of Low-Temperature Plasma Radiofrequency Ablation in the Treatment of Early Glottic Carcinoma. PMID 40497713 · Altern Ther Health Med · 2025-Jul The study is a randomized controlled trial in oncology (glottic carcinoma) with original results, but it is excluded because it does not meet the phase III/IIIb or Phase II/III requirement (no phase information provided, likely Phase II or other), the intervention is a device (radiofrequency ablation) without a drug component, and the endpoints are not time-to-event (e.g., recurrence rate is reported but not as a time-to-event endpoint with Kaplan-Meier or HR; voice recovery, complications, mucosal smoothness are not time-to-event). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients undergoing laparoscopic versus open hemihepatectomy: a secondary analysis of the ORANGE II PLUS randomised controlled, phase 3, superiority trial. PMID 40491830 · Lancet Reg Health Eur · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Video Versus Face-To-Face Preoperative Anaesthetic Assessment: The VIDFACE Trial-A Statistical Analysis Plan. PMID 40467292 · Acta Anaesthesiol Scand · 2025-Jul The record is a protocol for a non-oncology randomized trial assessing a preoperative assessment method, not a drug intervention, and lacks time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial. PMID 40466319 · Gynecol Oncol · 2025-Jul Study is a randomized trial in gynecologic oncology but evaluates a non-drug intervention (self-hypnosis) and measures patient-reported pain and anxiety as primary/secondary endpoints, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. PMID 40461939 · Clin Pharmacokinet · 2025-Jul The record describes a pharmacokinetic/cellular kinetics modeling study of ide-cel within a randomized trial (KarMMa-3). While the trial itself is randomized and the study mentions an association with PFS (time-to-event), the report is a secondary mechanistic analysis, not a primary or key secondary efficacy result report. The phase of the trial is not explicitly stated in the provided metadata, and the analysis does not present formal efficacy results for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study). PMID 40449127 · Gynecol Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer. PMID 40411966 · Gynecol Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects. PMID 40382284 · EBioMedicine · 2025-Jul The record is from a Phase III randomized trial in oncology with a drug intervention. However, the reported analysis is a pharmacogenomic/circadian sub-study focused on correlating gene expression changes with treatment toxicity. The primary efficacy endpoints of the trial (likely OS or PFS) are not presented or analyzed in this abstract; it is a mechanistic/toxicity-focused secondary analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial. PMID 40378895 · Radiother Oncol · 2025-Jul This is a report of a Phase III randomized clinical trial for cancer (vertebral oligometastases), with a primary time-to-event efficacy endpoint (overall survival, local failure). However, the intervention is radiotherapy (SBRT), not a drug-containing intervention. Therefore, it does not meet the eligibility criteria requiring a drug-containing intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison. PMID 40354013 · Adv Ther · 2025-Jul The record describes a matching-adjusted indirect comparison (MAIC) that synthesizes data from multiple trials (CARTITUDE-4, ELOQUENT-3, IKEMA, ICARIA-MM, BOSTON). It is not an original result report of a single Phase III/IIIb or Phase II/III randomized trial. Therefore, it does not meet the 'original_result' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial. PMID 40340551 · J Clin Oncol · 2025-Jul The study is a Phase III randomized trial in human oncology with original results, but it does not meet two key eligibility criteria: it lacks a time-to-event primary/key secondary endpoint (it uses a binary pain response outcome) and lacks a drug-containing intervention (it compares two radiotherapy regimens). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes and quality of life of laparoscopic-assisted pylorus-preserving gastrectomy compared to laparoscopic-assisted distal gastrectomy with billroth I anastomosis for early gastric cancer(pT1N0M0): A Randomized Controlled Trial. PMID 40318389 · Am J Surg · 2025-Jul 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU. PMID 40317957 · Aliment Pharmacol Ther · 2025-Jul The record describes a randomized trial of anti-TNF therapy in inflammatory bowel disease, which is not a malignant neoplasm. It is excluded based on the non-oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML. PMID 40298352 · Am J Hematol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial. PMID 40288687 · Radiother Oncol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. PMID 40280776 · Eur Urol · 2025-Jul The study is an oncology randomized trial with a time-to-event endpoint, but it lacks a drug intervention (it tests a diagnostic biomarker for guiding follow-up cystoscopy, not a therapeutic agent). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. PMID 40214720 · Am J Clin Dermatol · 2025-Jul The report is excluded because it is not an oncology study (alopecia areata is not a malignant neoplasm) and it lacks a primary/key secondary time-to-event efficacy endpoint, focusing instead on safety outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. PMID 40192993 · Ann Surg Oncol · 2025-Jul While the study is a randomized, oncology trial with time-to-event endpoints and a drug intervention, the provided evidence does not confirm it is a Phase III/IIIb or Phase II/III trial. Furthermore, the randomized portion was explicitly designated as exploratory due to design amendments, so it does not qualify as an original formal-result report of a definitive trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. PMID 40188007 · Int J Gynecol Cancer · 2025-Jul 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study. PMID 40181512 · Prostate · 2025-Jul The record is a pre-specified sub-analysis of a randomized trial, not the primary result report of the main trial, and does not provide definitive evidence of Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. PMID 40180121 · Ann Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Contact X-ray brachytherapy in rectal cancer: A systematic review and meta-analysis. PMID 40174334 · Eur J Surg Oncol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants. PMID 40159671 · Clin Pharmacol Ther · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Timing of advance care planning in patients with advanced cancer: Analysis of ACTION data. PMID 40158245 · Patient Educ Couns · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lower Testosterone Level and Metastases-Free Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Novel Antiandrogens: A Post Hoc Analysis of SPARTAN and ARAMIS. PMID 40132221 · J Urol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| What are the outcomes for long-term survivors after esophagectomy ? - Evidence from a randomized controlled trial (FFCD9901). PMID 40120352 · Eur J Surg Oncol · 2025-Jul 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Timing of Adjuvant Chemotherapy After Surgical Resection for Non-small Cell Lung Cancer: A Target Trial Emulation Using Nationwide Swedish Registry Data. PMID 40106109 · Ann Surg Oncol · 2025-Jul The study is an observational target-trial emulation using registry data, not a prospective randomized controlled trial. It does not report a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. PMID 40056922 · Lancet Infect Dis · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |